Related Experiment Video
Updated: Jun 19, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Pramipexole: a nonergot dopamine agonist as drug therapy in Parkinson's disease
1The Ohio State University, Parkinson's Center, 1581 Dodd Drive, Suite 371, Columbus, Ohio 43210, USA.
Abstract:
Pramipexole is a dopamine agonist that was recently introduced for the treatment of both early and advanced Parkinson's disease. Pramipexole is a synthetic aminobenzothiazole compound with a high affinity to D(3) receptors. It directly stimulates dopamine receptors without requiring metabolic conversion. Pramipexole is rapidly absorbed with bioavailability greater than 90% and is actively secreted by the renal tubules. The drug's plasma half-life is 8-12 h. Shown to be safe and effective as add-on therapy, pramipexole can also be used as initial dopaminergic therapy in Parkinson's disease, delaying the introduction of levodopa thereby postponing levodopa's side-effects.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Alterations in Muscle Tone lll
